Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Xeno Cell Innovations S R O maintains a focused presence in the Biotechnology & Pharmaceuticals technology area. The current prosecution profile is defined by 1 pending office action, representing the total active dialogue with the patent office. This specific matter is assigned to CLOW, LORI A, who serves as the busiest examiner for the portfolio. The emphasis on this sector indicates a specialized research and development focus.
The data reflects a singular point of contact within the USPTO, as the company is working with 1 distinct examiner across a distinct art unit. With CLOW, LORI A overseeing the busiest examiner pending action, the firm's immediate patenting success relies on the examination style of a single official. This lack of distribution across different art units or examiners means that the company faces a consolidated set of procedural expectations. For a practitioner, this indicates that the current prosecution strategy is entirely focused on a single technical niche and the specific interpretation of the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLOW, LORI A | 1 | 64.2% | +28.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17268340 | BIOLOGICAL COMPUTING SYSTEMS AND METHODS FOR MULTIVARIATE SURFACE ANALYSIS AND OBJECT DETECTION | CLOW, LORI A | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17268340 | BIOLOGICAL COMPUTING SYSTEMS AND METHODS FOR MULTIVARIATE SURFACE ANALYSIS AND OBJECT DETECTION | CLOW, LORI A | 1687 | §103 | Non-Final OA | 49d overdue | Pending | Feb 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXeno Cell Innovations S R O has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Lori A Clow has the most, with 1 of Xeno Cell Innovations S R O's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.